AbbVie stock: Cantor lifts target for AbbVie stock from USD 285 to USD 290

Published on 10/20/2026 at 15:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie will report third-quarter results on October 30, 2026. AbbVie stock costs EUR 256.40 on October 20, 2026, up 1.42 percent versus the Xetra close.

Analyst target and results date

Cantor Fitzgerald raised AbbVie's target from USD 285.00 to USD 290.00 on October 8, 2026.
AbbVie reported second-quarter revenue of USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock costs EUR 256.40 at Lang & Schwarz on October 20, 2026 at 5:35 p.m. CEST, 1.42 percent above the Xetra close of October 19, 2026, and 1.23 percent below its 52-week high.
AbbVie will report third-quarter results on October 30, 2026.

Isometrische 3D-Illustration des Drug-Discovery-Prozesses von Molekülforschung bis Marktzulassung — AbbVie Inc. US00287Y1091 isometrische 3D Darstellung Drug Discovery Prozess von Molekül Studie bis Marktzulassung, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) received a Cantor Fitzgerald target increase from USD 285.00 to USD 290.00 on October 8, 2026, according to MarketBeat. The new target stood 0.35 percent above AbbVie's USD 289.00 NYSE quote at 9:43 a.m. ET on October 20, 2026. At Lang & Schwarz, the stock was trading at EUR 256.40 on October 20, 2026 at 5:35 p.m. CEST, up 1.42 percent versus the Xetra close of October 19, 2026 at EUR 252.80.

Revenue growth sets the next test

AbbVie reported second-quarter 2026 revenue of USD 16.99 billion, up 10.20 percent from the same quarter a year earlier, while quarterly earnings per share reached USD 3.65 versus a USD 3.61 consensus estimate, MarketBeat reported. The revenue figure gives the October 30 report a measurable operating benchmark, while the earnings comparison indicates that the prior quarter exceeded expectations by USD 0.04 per share.

Stock stays near its yearly high

AbbVie's NYSE quote was USD 289.00 at 9:43 a.m. ET on October 20, 2026. The 52-week range was USD 190.75 to USD 291.40 as of October 20, 2026, placing the quote 0.69 percent below the high; the Lang & Schwarz price was 1.23 percent below the same high in euro terms.

What does the target imply?

Cantor Fitzgerald's USD 290.00 target was 0.35 percent above the USD 289.00 NYSE quote on October 20, 2026. AbbVie carried a USD 510.7 billion market capitalization, a 79.67 price-to-earnings ratio and a 2.00 percent dividend yield as of October 20, 2026. The company had scheduled its third-quarter 2026 results for October 30, 2026, before the market opened, according to AbbVie.

Valuation leaves little room for delay

For investors, the upcoming report must be read against both the USD 290.00 target and the USD 16.99 billion second-quarter revenue base. The 1.23 percent gap between the euro quote and its 52-week high keeps the price position close to its recent peak, while the 79.67 earnings multiple makes the October 30 figures the next concrete test of that valuation.

AbbVie and healthcare peers

AbbVie: up 1.42 percent versus the Xetra close, price-to-earnings ratio 79.67, market capitalization USD 510.7 billion as of October 20, 2026. Johnson & Johnson (NYSE, USD): up 2.47 percent, price-to-earnings ratio 39.35, market capitalization USD 626.7 billion as of October 20, 2026. Merck & Co. (NYSE, USD): up 3.78 percent, price-to-earnings ratio 119.17, market capitalization USD 367.8 billion as of October 20, 2026.

Price and reporting date

AbbVie stock was trading at EUR 256.40 at Lang & Schwarz on October 20, 2026 at 5:35 p.m. CEST, 1.42 percent above the Xetra close of October 19, 2026 at EUR 252.80. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.